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PRisk Stratification for Primary
Implantation of a Cardioverter-Defibrillator in
Patients With Ischemic Left Ventricular Dysfunction
Ilan Goldenberg, MD,* Anant K. Vyas, MD, MPH,† W. Jackson Hall, PHD,‡ Arthur J. Moss, MD,*
Hongyue Wang, PHD,‡ Hua He, MA,‡ Wojciech Zareba, MD, PHD,* Scott McNitt, MS,*
Mark L. Andrews, BBA,* for the MADIT-II Investigators
Rochester and Buffalo, New York
Objectives The study was designed to develop a simple risk stratification score for primary therapy with an implantable
cardioverter-defibrillator (ICD).
Background Current guidelines recommend primary ICD therapy in patients with a low ejection fraction (EF). However, the
benefit of the ICD in the low EF population may not be uniform.
Methods Best-subset proportional-hazards regression analysis was used to develop a simple clinical risk score for the end
point of all-cause mortality in patients allocated to the conventional therapy arm of MADIT (Multicenter Auto-
matic Defibrillator Implantation Trial)-II after excluding a pre-specified subgroup of very high-risk (VHR) patients
(defined by blood urea nitrogen [BUN] 50 mg/dl and/or serum creatinine 2.5 mg/dl). The benefit of the ICD
was then assessed within risk score categories and separately in VHR patients.
Results The selected risk score model comprised 5 clinical factors (New York Heart Association functional class II, age
70 years, BUN 26 mg/dl, QRS duration 0.12 s, and atrial fibrillation). Crude mortality rates in the conven-
tional group were 8% and 28% in patients with 0 and 1 risk factors, respectively, and 43% in VHR patients.
Defibrillator therapy was associated with a 49% reduction in the risk of death (p  0.001) among patients with
1 risk factors (n  786), whereas no ICD benefit was identified in patients with 0 risk factors (n  345; hazard
ratio 0.96; p  0.91) and in VHR patients (n  60; hazard ratio 1.00; p  0.99).
Conclusions Our data suggest a U-shaped pattern for ICD efficacy in the low-EF population, with pronounced benefit in
intermediate-risk patients and attenuated efficacy in lower- and higher-risk subsets. (J Am Coll Cardiol 2008;
51:288–96) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.058r
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pata from major randomized trials have shown that the
mplantable cardioverter-defibrillator (ICD) provides a
eaningful and significant reduction in mortality in patients
See page 297
ith ischemic and nonischemic cardiomyopathy and an
jection fraction (EF) 30% to 35% as part of primary
revention strategy (1–6). Consequently, current guidelines
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upported by a research grant from Guidant Corp., St. Paul, Minnesota, to
he University of Rochester School of Medicine and Dentistry. Drs. Goldenberg,
yas, and Hall contributed equally to original concept and to authorship of this
nvestigation.h
Manuscript received May 31, 2007; revised manuscript received July 27, 2007,
ccepted August 20, 2007.ecommend primary ICD implantation in this relatively
arge population (7). However, the low-EF group has
onsiderable risk heterogeneity, and multiple factors may
nteract with EF to influence the risk of arrhythmic mor-
ality among patients with similar degrees of left ventricular
ysfunction. To date, risk stratification studies have shown
hat individual risk markers, including QRS duration, ad-
anced New York Heart Association (NYHA) functional
lass, inducibility with electrophysiological testing, or
ignal-averaged electrocardiography, have limited ability to
dentify patients who should receive an ICD for the primary
revention of sudden cardiac death (3,8–10). It is possible
hat assessment of multiple risk factors can more clearly
elineate risk groups in whom ICD efficacy may be differ-
nt. Specifically, a lower-risk group may exist in the low-EF
opulation in which relatively low mortality rates may
reclude a meaningful ICD benefit within a reasonable time
orizon. Conversely, among patients with major comorbidi-
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January 22, 2008:288–96 MADIT-II Risk Scoreies and advanced cardiac disease, the short-term risk of
onarrhythmic mortality may predominate despite ICD
herapy.
We developed a simple clinical risk score based upon
nalysis of outcomes of patients allocated to the conven-
ional therapy arm of MADIT (Multicenter Automatic
efibrillator Implantation Trial)-II after excluding a pre-
pecified subgroup of very high-risk (VHR) patients with
omorbidities and advanced cardiac disease. The survival
enefit with an ICD was then evaluated in low- and
igher-risk patients identified by the risk score and sepa-
ately in patients with VHR.
ethods
tudy population. The design and results of MADIT-II
ave been reported elsewhere (3). In brief, 1,232 patients
ith documented previous myocardial infarction (MI) and
F 30% were randomized to receive a prophylactic ICD
r conventional medical therapy in a 3:2 ratio and were
ollowed over a mean period of 20 months. Screened
atients were excluded if they were in NYHA functional
lass IV at enrollment; had undergone coronary revascular-
zation within the preceding 3 months; had MI within the
ast month; had advanced cerebrovascular disease; had
lood urea nitrogen (BUN) 70 mg/dl or creatinine 3.0
g/dl (these thresholds were recommended; however, a few
xceptions occurred), or had any condition other than
ardiac disease that was associated with a high likelihood of
eath during the trial.
isk groups and outcome measures. Outcome analyses
ere carried separately in a pre-specified VHR group
subsequently defined), and the risk score was developed and
ssessed in the remaining study population.
HR GROUP. We hypothesized that the clinical course of
atients with left ventricular dysfunction who have addi-
ional major comorbidities is different from the remaining
tudy population because of a greater short-term mortality
isk in the former subgroup. Severe renal disease has been
hown to be a marker of advanced cardiovascular disease and
o be associated with high levels of mortality in patients with
schemic left ventricular dysfunction and heart failure (11–
3). Furthermore, data from MADIT-II have demon-
trated severe renal dysfunction to be the most powerful
redictor of all-cause mortality during the course of the trial
14). Consequently, the outcome of a relatively small sub-
roup of study patients (n  60) (Tables 1 and 2) who had
aseline laboratory data indicating advanced renal disease
pre-specfied as BUN 50 mg/dl and/or serum creatinine
2.5 mg/dl) was evaluated separately from the remaining
tudy population.
UTCOME MEASURES. The primary end point of the study
as death from any cause. Analysis was performed accord-
ng to the intention-to-treat principle. In a secondary
nalysis, we also evaluated the mode of death in risk score
croups with the use of a modified
inkle-Thaler system, as previ-
usly described (15), and the fre-
uency of appropriate ICD ther-
pies by risk groups with the use
f interrogation data of im-
lanted patients, as described
reviously (9).
tatistical analysis. VHR PA -
IENTS. Characteristics in the 2
reatment groups within the
HR group were compared with
he Wilcoxon rank sum, chi-
quare, or Fisher exact test, as
ppropriate. Kaplan-Meier estimates for survival in VHR
atients by treatment group were determined and statisti-
ally evaluated with the log-rank test. The Cox proportional
azards regression model was used to evaluate the contri-
ution of treatment assignment to the development of
ll-cause mortality.
EVELOPMENT AND EVALUATION OF RISK SCORE IN THE
AIN STUDY POPULATION (NON-VHR PATIENTS). Analyses
ere based on the 467 patients allocated to conventional
edical therapy and 705 patients allocated to ICD therapy
n MADIT-II not falling in the VHR group. We pre-
pecified 17 potential clinical, electrocardiographic, and
aboratory risk factors (Table 3, including first footnote) for
he risk model. Thresholds for categorization of numerical
ariables into lower-risk and higher-risk subsets were pre-
pecified with the use of clinical and laboratory accepted
aseline Characteristics, and Mortality, of the Totaltudy Popul tion, by Very High-Risk Patien s (VHRroup)* Versus All O h r Study (Non-VHR) Patien s
Table 1
Baseline Characteristics, and Mortality, of the Total
Study Population, by Very High-Risk Patients (VHR
Group)* Versus All Other Study (Non-VHR) Patients
VHR Patients
(n  60)
Non-VHR Patients
(n  1,172)
Characteristic
BUN, mg/dl 58 (54, 66) 29 (26, 15)†
Creatinine, mg/dl 2.3 (2.6, 1.9) 1.1 (1.3, 0.96)†
Age, yrs 72 (77.5, 66) 65 (72, 57)†
Ejection fraction 20 (25, 17) 25 (28, 20)†
NYHA (% in I, II, III–IV)‡ 23%, 23%, 53% 37%, 36%, 24%†
QRS duration, ms 130 (160, 100) 110 (140, 100)†
Atrial fibrillation, n (%)§ 7 (12) 98 (8)
Female, n (%) 9 (15) 183 (16)
Diuretic therapy, n (%) 55 (92) 866 (74)†
Digitalis therapy, n (%) 36 (60) 685 (58)
Mortality
Crude rate, n (%) 29 (48) 183 (16)†
Adjusted rate, %¶ 3.0% 0.7%†
Defined as having BUN 50 mg/dl or serum creatinine 2.5 mg/dl; entries are presented as
edian (quartiles) or percentages. †All p values, for appropriate tests comparing VHR with
on-VHR patients, are0.005 except for atrial fibrillation, female gender, and digitalis therapy, for
hich each p exceeds 0.35. ‡Values reflect the highest New York Heart Association (NYHA)
unctional class recorded in the 3-month period before enrollment. Eligibility was limited to
atients who were in NYHA functional class I, II, or III at the time of enrollment. §Identified as
aseline rhythm at enrollment. ¶Number of deaths per number of patient months at risk, in
Abbreviations
and Acronyms
BUN  blood urea nitrogen
EF  ejection fraction
ICD  implantable
cardioverter-defibrillator
LBBB  left bundle branch
block
MI  myocardial infarction
NYHA  New York Heart
Association
VHR  very high riskontrast to the crude rates in the previous line.
BUN  blood urea nitrogen; VHR  very high risk.
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MADIT-II Risk Score January 22, 2008:288–96riteria. Univariate relationships between candidate risk
actors and all-cause mortality in the conventional therapy
roup were assessed with Cox proportional hazards regres-
ion analysis. Risk factors with a hazard ratio 1.3 and a
value 0.20 were further evaluated by conducting out a
est-subset proportional-hazards regression analysis in the
onventional therapy group, using a penalty of 3.84 on the
ikelihood ratio chi-square value for each factor included
this methodology corresponds to stepwise regression with a
aseline Characteristics, and Mortalityf V ry Hig -Risk Patients* by Treatment Arm
Table 2 Baseline Characteristics, and Mortalityof Very High-Risk Patients* by Treatment Arm
Conventional Group
(n  23)
ICD Group
(n  37)
Characteristic
BUN, mg/dl 59 (54, 66) 57 (54, 66)
Creatinine, mg/dl 2.2 (2.0, 2.6) 2.4 (1.8, 2.7)
Age, yrs 70 (65, 77) 73 (66, 78)
Ejection fraction 25 (20, 27) 20 (15, 25)
NYHA (% in I, II, III–IV)‡ 22%, 22%, 57% 24%, 24%, 51%
QRS duration, ms 120 (100, 150) 140 (110, 170)
Atrial fibrillation, n (%)§ 6 (26%) 1 (3%)†
Female, n (%) 4 (17) 5 (14)
Diuretic therapy, n (%) 22 (96) 33 (89)
Digitalis therapy, n (%) 13 (57) 23 (62)
Mortality
Crude rate, n (%) 10 (43) 19 (51)
Adjusted rate, %§ 3.0% 2.9%
Defined as having BUN 50 mg/dl or serum creatinine 2.5 mg/dl; data are presented as
edian (quartiles) or percentages. †For atrial fibrillation, p 0.01 by Fisher exact test; for ejection
raction, p  0.13 by Wilcoxon rank test; all other p values for appropriate tests exceed 0.20.
Values reflect the highest NYHA functional class recorded in the three-month period before
nrollment. Eligibility was limited to patients who were in NYHA functional class I, II, or III at the
ime of enrollment. §Identified as baseline rhythm at enrollment. ¶Number of deaths per number
f patient-months-at-risk, in contrast to the crude rates in the line above.
ICD  implantable cardioverter-defibrillator; other abbreviations as in Table 1.
otential Baseline Variables for Defining High- and Lower-Riska gories nd Associated Risk in the Conventional Th apy Group
Table 3 Potential Baseline Variables for Defining High- and LowCategories and Associated Risk in the Conventional Th
Variable
High-Risk Category
Definition n†
Mortality Rate‡
Crude, % Adjusted
Atrial fibrillation Yes 36 39 2.06
BUN, mg/dl 26 122 29 1.63
NYHA functional class II 117 31 1.55
Age, yrs 70 143 27 1.46
LBBB Yes 75 31 1.62
QRS duration, ms 120 152 27 1.43
Creatinine, mg/dl 1.3 129 27 1.46
Ejection fraction, % 20 96 30 1.35
Heart rate, beats/min 80 120 28 1.30
Prior 1-yr hospitalization# 1 120 27 1.26
Body mass index, kg/m2 25 135 27 1.26
Diabetes mellitus Yes 176 25 1.20%
Analysis was conducted in 467 patients after excluding 23 VHR patients (see Table 1) variables a
lood pressure 100 mm Hg, history of smoking, history of ventricular tachyarrhythmias, treated
f conventional group patients in respective risk category. For each variable, only patients with co
atients, respectively, are omitted due to missing information; other variables had 9 (2%) missi
alculated as number of deaths per patient months at risk (represents the estimated chance of
igh-risk relative to lower-risk categories (ratio of the adjusted rates approximates the HRs). Defined in T
HR  hazard ratio; LBBB  left bundle branch block; other abbreviations as in Table 1.value of 5%). Model selection was repeated after dropping
nselected factors, one at a time, to minimize effects of
issing data.
After selection of risk factors, a simple risk score was
onstructed as a count of risk factors identified in each
atient. Crude death rates across risk groups were compared
y chi-square tests. Survival curves, by the Kaplan-Meier
ethod, were constructed in various risk categories for
onventional and for ICD patients, with p values by the
og-rank test. Proportional-hazards regression analyses were
onducted in the full non-VHR group, with the following
ovariates: risk score group (2 or 4 covariates), treatment
rm (2 covariates), and their interactions (ICD effect in each
isk score group). Checks were made for validity of the
roportional-hazards assumption.
ENSITIVITY AND CROSS-VALIDATION STUDIES. Sensitivity
nalyses were carried out by considering other choices of risk
actors for the risk score. Cross-validation analyses were also
onducted A more detailed description of these analyses is
resented in the Online Appendix. Analyses were per-
ormed with the use of SAS software (version 9.1, SAS
nstitute, Cary, North Carolina) and Splus 7.0 (Insightful
orporation, Seattle, Washington).
esults
HR group. Sixty study patients (5%) met the criteria for
his risk category and were evaluated separately from the
ain study population. In addition to markers of advanced
enal dysfunction, patients with VHR were demonstrated to
ave a significantly greater proportion of high-risk clinical
haracteristics compared with non-VHR patients (Table 1),
ncluding an older age, a more advanced NYHA functional
sk
y Group*
Lower-Risk Category High:Low§
Definition n†
Mortality‡
HR p ValueCrude, % Adjusted, %
No 426 19 0.89 2.39 0.001
26 338 18 0.79 2.12 0.001
II 342 17 0.77 2.02 0.001
70 324 18 0.78 1.92 0.002
No 361 19 0.87 1.87 0.010
120 308 18 0.78 1.86 0.003
1.3 333 18 0.81 1.85 0.004
20 371 18 0.85 1.58 0.040
80 346 18 0.84% 1.55 0.040
1 306 17 0.82 1.55 0.051
25 331 18 0.83 1.51 0.050
No 290 18 0.82 1.48 0.057
in the order of decreasing hazard ratios; other variables considered were female gender, systolic
nsion, but none of them had a hazard ratio 1.30 nor a p value 0.20. †n denotes the number
baseline data were included: for prior year hospitalizations and for LBBB, 41 (9%) and 31 (7%)
. ‡Crude rates were calculated as number of deaths per number of patients; adjusted rates were
ithin a month). §Results are from a single-variable proportional-hazards regression analysis for*
er-Ri
erap
, %
re listed
hyperte
mplete
ng data
dying wable 1. #Denotes the number of hospitalizations for all causes during the year before enrollment.
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January 22, 2008:288–96 MADIT-II Risk Scorelass, a lower ejection fraction, a longer QRS duration on
he baseline electrocardiogram, and a greater frequency of
aseline medical therapy with diuretics. Forty-eight percent
f the patients in the VHR group died during the course of
he trial, whereas crude mortality rate in non-VHF patients
as 16%.
Clinical characteristics among VHR patients were similar
n the ICD and conventional therapy groups, and adjusted
ortality rates were virtually identical in the 2 treatment
roups (Table 2). Accordingly, the survival curves for the
CD and conventional therapy groups were similar (Fig. 1),
ith an overall 2-year mortality of approximately 50% and
ith an ICD/conventional hazard ratio of 1.00 (95% con-
dence interval 0.5 to 2.2, p  0.99) in this risk category.
isk score and outcome in the main study population
non-VHR patients). MODEL SELECTION. Analyses for
he selection of the risk score model were based on the 467
atients allocated to the conventional therapy group in
ADIT-II not falling in the VHR group. Of the 17
ariables that were pre-specified as potential risk-stratifiers,
(female gender, a history of treated hypertension, previous
ocumented ventricular tachyarrhythmias, systolic blood
ressure 100 mm Hg, and smoking at any time) had
azard ratios 1.30 and p values exceeding 0.20 for all-
ause mortality and were therefore dropped from further
onsideration as candidates for risk stratification. The re-
aining 12 variables were considered extensively for the
evelopment of the risk score (Table 3). When considered
lone, the first 7 (atrial fibrillation [defined as the baseline
hythm at enrollment], BUN 26 mg/dl, NYHA func-
ional class II [defined as the highest functional class
ecorded in the 3-month period before enrollment], age
70 years, the presence of left bundle branch block
LBBB], a QRS duration 0.12 s, and serum creatinine
1.3 mg/dl) had hazard ratios for mortality in convention-
lly treated patients of 1.85 or greater and with p values
Figure 1 Probability of Survival in VHR Patients
Kaplan-Meier estimates of the probability of survival, by treatment group, in
very high-risk (VHR) patients. CONV  conventional therapy group; ICD 
implantable cardioverter-defibrillator.30.005 (except for LBBB, having smaller numbers because
f missing data). The remaining 5 (EF 20%, heart rate
80 beats/min, number of hospitalizations in the year
efore enrollment 1, body mass index 25 kg/m2, and a
istory of treated diabetes mellitus) had hazard ratios
anging from 1.58 down to 1.48, with p values ranging from
.04 to 0.06. The best-subset proportional-hazards regres-
ion, using these 12 binary covariates, led to a model with
he 5 risk factors: age, NYHA functional class, BUN, atrial
brillation, and QRS duration (Table 4). Although high
evels of creatinine and the presence of LBBB were found to
e powerful univariate predictors of outcome, these 2 risk
actors did not provide incremental prognostic information
hen elevated BUN and a wide QRS duration (0.12 s),
espectively, were allowed in the multivariate model.
UTCOME BY RISK SCORE. A simple risk score was con-
tructed as a count of risk factors identified in each patient,
mong the selected 5 (age, NYHA functional class, BUN,
trial fibrillation, and QRS duration). Risk score counts
ere truncated at 3 because of small numbers of patients
ith counts of 4 or 5 risk factors.
The counts of deaths and crude mortality in each of the
arious strata, by treatment arm, are presented in Table 5.
rude mortality was similar in the ICD and conventional
herapy groups among patients in whom none of the 5 risk
actors were present. The lower-risk group with 0 risk
actors comprised almost one-third of the study population.
y contrast, among patients with 1 risk score factors,
rude mortality rates were lower in ICD patients than
mong patients in the conventional therapy group. Consis-
ently, the 2-year Kaplan-Meier probabilities of death were
elatively low, and virtually identical, in the ICD and
onventional therapy groups among patients with 0 risk
actors (9% and 8%, respectively) (Fig. 2A), whereas among
atients with 1 risk factors, 2-year mortality rates were
ignificantly lower in the ICD group (15%) as compared
ith the conventional therapy group (27%, p 0.001) (Fig.
B). Notably, the difference in mortality rates between the
CD and conventional therapy groups was most prominent
mong patients with 1 or 2 risk factors (Table 5, Figs. 3A
nd B, respectively) who comprised more than one-half of
he patient population, whereas among patients with 3
isk factors, mortality was only slightly lower in the ICD
roup than in the conventional therapy group (Table 5,
ig. 3C).
Cox proportional-hazards modeling of mortality, using
he simple risk score stratifiers, treatment arm, and their
nteractions as covariates, demonstrated that in the conven-
ional therapy group each of the risk score strata had a
ighly significant hazard ratio for mortality compared with
he group with no risk factors (Table 6). Patients with 1
isk factors exhibited more than a 4-fold increase in the risk
f death compared with patients with no risk factors.
urthermore, significant differences were found among the
strata with 1, 2, or 3 risk factors (p  0.04).
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MADIT-II Risk Score January 22, 2008:288–96When the ICD/conventional risk of death was analyzed
y risk score strata, no evidence of an ICD effect was shown
mong patients with 0 risk factors (hazard ratio 0.96; p 
.91), whereas among patients with 1 risk factor, ICD
herapy was associated with a significant 49% reduction in
he risk of death (Table 6). Consistent with the Kaplan-
eier estimates in Figure 3, the benefit of ICD therapy was
ore prominent among patients with 1 (60% risk reduction;
 0.002) and 2 (58% risk reduction; p  0.001) risk
actors than among patients with 3 risk factors (20% risk
eduction; p 0.44). The difference between the ICD effect
mong patients who had either 1 or 2 risk factors and the
ffect of the device among patients with 0 risk factors was
arginally significant (p value for the difference  0.05),
hereas no difference in ICD efficacy was shown between
atients with 3 risk factors and those with 0 risk factors
p  0.72).
-shaped pattern for ICD effect in the total study
opulation. The effect of the ICD among patients with
ncreasing mortality rates in the conventional therapy group
from 0 to 3 risk factors and VHR patients) showed a
ultivariate Proportional Hazards Regression Model:isk of All-Cause Mortality in the Conv nt alherapy Group for SelectedF ctors*†
Table 4
Multivariate Proportional Hazards Regression
Model: Risk of All-Cause Mortality in the
Conventional Therapy Group for Selected
Risk Factors*†
Risk Factor HR
95% Confidence
Interval p Value
NYHA functional class II 1.87 1.23–2.86 0.004
Atrial fibrillation‡ 1.87 1.05–3.22 0.034
QRS 120 ms 1.65 1.08–2.51 0.020
Age 70 yrs 1.57 1.02–2.41 0.042
BUN 26 mg/dl (and 50 mg/dl) 1.56 1.00–2.42 0.048
Analysis was conducted in 445 patients allocated to the conventional group: 23 VHR patients are
mitted, as well as 22 patients with missing information on one or more of the 5 risk factors.
Model was derived from a best subsets regression analysis (penalizing by 3.84 for each factor
ncluded) that was carried out for the 12 risk factors in Table 3. ‡Defined in Table 1.
Abbreviations as in Tables 1 and 3.
isk Score and Outcome in the Main Studyopulation: All-Ca se Mortality by Trea ment Group
Table 5 Risk Score and Outcome in the Main StudyPopulation: All-Cause Mortality by Treatment Group
Risk Group
Conventional Group ICD Group
Patients
(%)
Deaths
(%)†
Patients
(%)
Deaths
(%)†
All patients (non-VHR)* 445 (100) 94 (21) 686 (100) 88 (13)
By risk score*‡
0 149 (33) 12 (8) 196 (29) 14 (7)
1 296 (67) 82 (28) 490 (71) 74 (15)
1 128 (29) 28 (22) 209 (30) 19 (9)
2 100 (22) 32 (32) 186 (27) 27 (15)
3 68 (15) 22 (32) 95 (14) 28 (29)
VHR group§ 23 10 (43) 37 19 (51)
Analysis was conducted after omitting the VHR group; in addition, 22 conventional (1 death) and
9 ICD (0 deaths) patients were omitted due to missing information on risk factors. †Denotes the
umber of deaths and the corresponding crude mortality rate (deaths per number of patients in
ach category). ‡High-risk factors included in the risk score are New York Heart Association
unctional class II, atrial fibrillation, QRS duration 120 ms, age 70 years, and blood urear
itrogen 26 mg/dl. §Very high-risk patients are repeated from Table 1 for comparison.
Abbreviations as in Tables 1 and 2.-shaped pattern for ICD benefit (Fig. 4 and ICD/
onventional hazard ratios in Table 6). Thus, no significant
CD effect was observed among patients in whom 2-year
ortality rates with conventional therapy were very low or very
igh, whereas the benefit of device therapy was pronounced
mong patients with intermediate mortality rates.
ode of death and frequency of appropriate ICD ther-
py by risk-strata. Because the reduction in the risk of
ll-cause mortality with an ICD is expected to occur
hrough termination of life-threatening arrhythmic episodes
hat may lead to sudden cardiac death, defibrillator therapy
ay be less effective in subsets of patients with a relatively
ow risk of sudden cardiac death and ventricular tachyar-
hythmias or in whom nonarrhythmic mortality predomi-
ates. We therefore assessed the proportion of sudden
ardiac versus nonsudden (e.g., all other modes of death)
ortality and the rate of appropriate ICD therapy, in the
isk score groups and the VHR group.
Patients allocated to conventional medical therapy were
hown to experience increasing sudden cardiac mortality
Figure 2 Probability of Survival in
Patients With Risk Scores 0 and >1
Kaplan-Meier estimates of the probability of survival, by treatment group, in
(A) patients with risk score  0; and (B) patients with risk score 1. Analysis
was conducted after omitting VHR group; in addition, 22 conventional and 19
ICD patients were omitted due to missing information on risk factors. Abbrevia-
tions as in Figure 1.ates among those with increasing risk score groups of 0 to
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January 22, 2008:288–96 MADIT-II Risk Score, whereas among patients with3 risk factors and in VHR
atients the increase in sudden cardiac mortality was atten-
ated (Fig. 5A). In contrast, in the ICD group, crude
udden cardiac mortality rates were relatively low, and
imilar, among patients with risk scores of 0 to 2, and
ncreased among greater-risk patients. Notably, the pre-
ominant mode of death in the VHR group was nonsudden.
early 40% ICD-allocated patients in the VHR group
Figure 3 Probability of Survival in
Patients With Risk Scores 1, 2, and >3
Kaplan-Meier estimates of the probability of survival, by treatment group, in
(A) patients with risk score  1; (B) patients with risk score  2; and
(C) patients with risk score 3. Analysis was conducted after omitting VHR
group; in addition, 22 conventional and 19 ICD patients were omitted because
missing information on risk factors. Abbreviations as in Figure 1.xperienced nonsudden death during the course of the trial, vhereas only 13% of the patients in this risk category
xperienced sudden cardiac death (Fig. 5B).
There were 703 patients in the ICD group who received
efibrillators and had information on the risk factors con-
idered. Of the 189 patients with 0 risk factors, 18%
xperienced appropriate ICD therapy during an average
ollow-up time of 21 months as compared with 26% of the
80 patients with 1 risk factor who experienced such
herapy during an average follow-up time of 20 months
p  0.04). Of the 34 VHR patients with an ICD, 18%
xperienced defibrillator therapy during an average
ollow-up time of 16 months.
odel stability and sensitivity analyses. Several methods
ere used to validate the stability of model selection and its
elationship to ICD efficacy. The results of some of these
nalyses are described in the Online Appendix. In brief,
ensitivity analyses showed that when high BUN was
eplaced by high creatinine, or NYHA functional class by
ow EF, similar patterns were found. Other substitutions
esulted in weaker conclusions. Cross-validation analyses in
maller groups of conventionally treated patients yielded
nstable results for ICD efficacy, possibly due to sample size
imitations.
iscussion
e used the prognostic information from a multivariable
nalysis in MADIT-II patients who were treated with
onventional medical therapy to develop a convenient and
imple clinical risk score that was employed to stratify
igher- and lower-risk subgroups of low-EF patients for
rimary ICD implantation.
Our findings suggest that the benefit of primary ICD
herapy may be limited in 2 distinct subsets of MADIT-II
atients: 1) a very low-risk subset consisting of nearly
ne-third of study patients who did not have any risk score
actors at enrollment. Patients in this risk category were shown
o experience relatively low 2-year mortality rates without an
CD, thereby limiting a meaningful ICD effect within this
ime-period. 2) A small subset of VHR patients with comor-
idities and clinical markers suggestive of advanced cardio-
ascular disease. Patients in this latter risk category had
-year mortality rates of 50%, with or without an ICD, and
he predominant mode of death in this population was
onarrhythmic in nature, thus precluding a meaningful
CD effect on the risk of all-cause mortality. By contrast,
he benefit of ICD therapy was pronounced (60% reduction
n the risk of death compared with conventional medical
herapy) in more than one-half of study patients who had 1
r 2 risk score factors. In this subset of patients, the
ssociated 2-year probabilities of death without an ICD
ere 22% and 27%, respectively, whereas the respective
ortality rates in the ICD arm were 10% and 15%.
The U-shaped pattern of ICD benefit suggests a pro-
ounced benefit in intermediate-risk patients with left
entricular dysfunction and attenuated efficacy in lower- and
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MADIT-II Risk Score January 22, 2008:288–96igher-risk subsets. This relationship is consistent with
revious observations from primary ICD trials. Of the 7
andomized studies in which primary prevention with a
efibrillator was evaluated in low-EF patients, 5 showed a
eaningful 23% to 54% reduction in the risk of death with
CD therapy (1,3–6), whereas in CABG (Coronary Artery
ypass Graft)-Patch (10) and the DINAMIT (Defibrillator
n Acute Myocardial Infarction Trial) (16) no ICD benefit
as shown (hazard ratios 1.07 and 1.08, respectively).
otably, the latter 2 trials enrolled patients with a low risk
f arrhythmic death or a very high clinical risk, respectively.
nalysis of the CABG-Patch trial data revealed that the low
isk of arrhythmic mortality after coronary revascularization
esulted in a nonsignificant reduction in total mortality with
isk Score and Outcome in the Main Study Population: Multivariat
Table 6 Risk Score and Outcome in the Main Study Population
Risk Group n (%)‡
Main Effect in Conve
HR§ 95% Confidence I
All patients (non-VHR) 1,131 (100) NA
By risk score†
0 345 (31) 1.00 Reference
1 786 (69) 4.27 2.3–7.8
1 337 (30) 3.06 1.6–6.0
2 286 (25) 5.04 2.6–9.8
3 163 (14) 6.05 3.0–12.2
VHR group# 60 NA
Proportional hazards was conducted in 1,131 patients, after omitting the VHR group and 22 in th
actors. Models included treatment arm and either nothing more, or two risk groups (0 and 1), t
ith treatment arm. †High-risk factors included in the risk score are: New York Heart Association fu
g/dl. ‡Number of patients (percentage of total) with indicated number of high-risk factors (risk s
ests for the difference in HRs among the groups are as follows: among risk scores 0 to 3: p  0
atio for ICD relative to conventional in each risk group. Tests of the HR for ICD effect between pai
 0.05; risk score3 vs. 0: p 0.72; risk score1 vs. 0: p 0.14; among levels 0, 1, 2, and3:
Abbreviations as in Tables 1, 2, and 3.
Figure 4 U-Shaped Curve for ICD Efficacy
(A) Two-year Kaplan-Meier mortality rates in the ICD and conventional therapy
groups; and (B) the corresponding 2-year mortality rate reduction with an ICD,
by risk score and in VHR patients. *p  0.05 for the comparison between the
conventional therapy and ICD groups. Abbreviations as in Figure 1.in ICD during the course of the trial (17), whereas in
INAMIT enrollment of high-risk patients with left ven-
ricular dysfunction in the immediate postinfarction period
esulted in a high rate of nonarrhythmic mortality that may
ave attenuated the ICD effect on total mortality (16).
urthermore, subanalyses of the secondary prevention
IDS (Canadian Implantable Defibrillator Study) trial (18)
nd the first MADIT study (19) have consistently shown
he lack of a significant survival benefit with an ICD in a
elatively large subset of low-risk patients. Thus, it appears
hat careful selection of appropriate risk patients is critical
or obtaining a meaningful ICD effect in low-EF patients.
Presently, there are no validated criteria for selecting or
xcluding patients with reduced EF for prophylactic ICD
herapy. Signal-averaged electrocardiography and inducibil-
ty with electrophysiological testing were not shown to be
linically useful in risk stratification for primary ICD im-
lantation (9,10). Thus, EF remains the major eligibility
riterion for primary ICD implantation (7). Recently, mi-
rovolt T-wave alternans was shown to be an independent
redictor of nonfatal sustained ventricular arrhythmias or
eath in patients with left ventricular dysfunction and was
uggested to be useful to identify patients in whom primary
CD therapy may be beneficial (20). It should be noted,
owever, that the relation between this possible risk-stratifier
nd outcome was not compared between ICD- and non–ICD-
reated patients. Importantly, assessment of the risk of ven-
ricular arrhythmias or sudden cardiac death in patients
ithout a defibrillator does not always correlate with ICD
fficacy. Thus, it is possible that the association between the
resence of an abnormal microvolt T-wave alternans test
nd spontaneous ventricular arrhythmias may not identify
CD benefit in relatively low-risk patients, without addi-
ional clinical risk factors, or in very high-risk patients, who
lso have a high risk of nonarrhythmic mortality.
Our findings suggest that a simple clinical risk score that
lysis for the End Point of All-Cause Mortality*
tivariate Analysis for the End Point of All-Cause Mortality*
l Group ICD: Conventional
l p Value HR 95% Confidence Interval p Value
0.60 0.45–0.80 0.001
0.96 0.44–2.07 0.91
0.001 0.51 0.37–0.70 0.001
0.001 0.40 0.22–0.72 0.002
0.001 0.42 0.25–0.70 0.001
0.001 0.80 0.46–1.40 0.44
1.00 0.50–2.2 0.99
entional therapy group (1 death) and 19 ICD (0 deaths) patients with missing information on risk
nt arm, and interaction with treatment arm, or four risk groups, treatment arm, and interactions
l classII, atrial fibrillation, QRS duration120ms, age70 years, and blood urea nitrogen26
HR denotes hazard ratio for all-cause mortality relative to patients with none of the 5 risk factors.
mong risk scores 1 to 3: p  0.04; among levels 0 and 1 (see above). HR denotes the hazard
k groups yielded: risk score 1 vs. 0: p  0.08; risk score 2 vs. 0: p  0.08; risk score 1 or 2 vs. 0:
2. #Analysis in very high-risk patients was conducted separately and is shown here for comparison.e Ana
: Mul
ntiona
nterva
e conv
reatme
nctiona
core). §
.001; a
rs of risncludes age, heart failure functional class, BUN levels, QRS
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January 22, 2008:288–96 MADIT-II Risk Scoreuration, and the presence of atrial fibrillation can delineate
ower- and higher-risk subsets in the low EF population
hat correlate with ICD efficacy. Using this methodology,
e showed that despite the fact that ICD therapy was
ssociated with an overall significant 31% reduction in the
isk of death in the MADIT-II population, approximately
ne-third of enrolled patients who had none of the risk-
core factors had no identifiable benefit from the implanted
evice. These findings may also have important health-
conomic implications considering the high incremental
ost-effectiveness ratio for an ICD that was found in
ADIT-II (21).
tudy limitations. Patients in MADIT-II were followed-up
or a relatively short period of time during the trial (mean
eriod, 20 months, and up to 4 years). Therefore, further
tudies are needed to validate the consistency of the current
Figure 5 Mode of Death by Risk Group
Percent of sudden cardiac deaths (SCD) and nonsudden deaths (e.g., all other
modes of all-cause mortality) presented as the number of deaths per number
of patients in each risk category, in (A) the conventional therapy group and
(B) the ICD group. The mode of death was not determined in 28 (15%) cases
that were distributed similarly among risk groups and omitted. Abbreviations as
in Figure 1.isk stratification scheme during longer time-periods after dCD implantation. The MADIT-II protocol excluded most
atients with BUN 70 mg/dl or creatinine 3.0 mg/dl.
ccordingly, the VHR group in the current study consisted
f only 60 patients, and the findings regarding lack of an
CD effect in this population should be regarded as prelim-
nary and exploratory. Nevertheless, the exceedingly high
ate of nonarrhythmic death in VHR patients who were
reated with an ICD suggests that the effect of device
herapy on total mortality in this risk group may be limited.
hus, the efficacy of ICD therapy in patients with BUN
50 mg/dl and/or serum creatinine 2.5 mg/l should be
valuated separately in future trials. At present, our findings
uggest caution when considering primary ICD implanta-
ion in patients with advanced renal dysfunction.
Low-risk patients with 0 risk factors comprised approx-
mately one-third of study patients. However, the statistical
ower of this analysis to detect a significant ICD effect in
he lower-risk subset was limited because of a low event rate.
t appears that very large trials would be needed to establish
fficacy in such groups. Our data suggest that an ICD may
ot provide a meaningful effect in low-risk patients during
he first 2 years after implantation because of a relatively low
isk of arrhythmic mortality during this time period.
It should also be noted that the analyses of the simple risk
core are potentially biased because the conventional arm
ata were used to construct the score, as well as to evaluate
t using ICD-arm and conventional-arm data. Possibly
ecause of sample size limitations, cross-validation analyses
n smaller data sets did not facilitate the development of a
omparable risk score or statistically significant evaluations
f ICD effects. Our evaluation of 2 less-efficient risk scores,
oth giving similar results, provides some support for our
eneral conclusions. Still, our results need to be considered
argely descriptive of what occurred in the MADIT-II
tudy, rather than predictive of what might occur in other or
uture settings. Thus, there is great need to conduct similar
nalyses in other sets of clinical trial data. These analyses
ould provide important confirmatory data for the proposed
isk-stratification score.
onclusions and Possible Clinical Implications
ur findings suggest that a simple risk score, comprising 5
linical risk factors, can be used to identify a relatively large
ower-risk subset in the post-MI, low-EF population, in
hom the short-term survival benefit of an ICD may be
imited. Importantly, it should be noted that risk factors in
atients with acquired cardiac disorders are dynamic and
ime-dependent. Therefore, careful follow-up and continu-
us risk-assessment should constitute an important compo-
ent in the management of low-risk patients considered for
rimary ICD implantation. Our preliminary findings re-
arding the high rate of nonarrhythmic mortality in ICD-
reated patients with comorbidities and advanced cardiac
isease suggest that newer and more effective means are
n
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MADIT-II Risk Score January 22, 2008:288–96eeded to prevent heart failure progression and death after
CD implantation in this high-risk population.
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APPENDIX
or additional discussion regarding sensitivity and cross-validation studies,
lease see the online version of this article.
